Drugs / Tapentadol ER
Tapentadol ER
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01309386 | Aug 2010 → Jan 2012 | neoplasm | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tapentadol ER | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01309386 ↗ |
| Known as | JNS024ER | “The purpose of this study is to evaluate the conversion rate based on the number of participants achieving pain control and safety within 1 week after switching the opioid...” NCT01309386 ↗ |
| Known as | tapentadol extended-release | “The purpose of this study is to evaluate the conversion rate based on the number of participants achieving pain control and safety within 1 week after switching the opioid...” NCT01309386 ↗ |
| Route | Oral | “Tapentadol ER 100 to 400 milligram (mg) orally daily for 8 weeks” NCT01309386 ↗ |